Valbiotis SA (FR:ALVAL) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Valbiotis announced the success of its INSIGHT clinical study, demonstrating that TOTUM•854 significantly reduces systolic blood pressure in individuals with untreated mild hypertension. This success marks TOTUM•854 as a promising non-drug solution for cardiovascular disease prevention, aligning with Valbiotis’ mission to improve health through innovative plant-based products.
For further insights into FR:ALVAL stock, check out TipRanks’ Stock Analysis page.